Tuberculosis remains a major public health problem despite the implementation of many strategies from fight, essensially based on antituberculosis treatment. However, these drugs can cause quite common side effects include potentially serious hepatotoxicity, often posing a management problem. To assess this complication of Antituberculosis treatment, we conducted a descriptive retrospective study of 80 cases of hepatotoxicity, listed by the Pharmacovigilance Unit of department Pharmacology-toxicology in UHC Ibn Rochd of Casablanca for the past seven years from January 2008 to December 2014. Hepatotoxicity represented 10% (80 cases) of all notifications of adverse drug reactions. The middle age of patients was 28 years, with a female predominance and a sex ratio W/M of 1,74. 75% of patients were under the combination of four antituberculosis drugs (RHZE); 32.5% were taking other drugs associated with antituberculosis regimen can be increased the risk of occurrence of this EIM. 2/3 of the patients had a period of occurrence of hepatotoxicity between 1 and 20 days. The clinical and biological profile most predominant was the cytolytic hepatitis (50%). The interruption of treatment was recommended in (88.75%). Regression of hepatotoxicity was observed in 80% of patients after antituberculosis treatment stop. The evolution was favorable in 40% of cases. The establishment of well codified recommendations is necessary to minimize the risk of occurrence of this adverse effect by enabling better tolerance and compliance.